US · Healthcare · Biotechnology
EPS came in at 0.88 against a street estimate of 0.91 — a miss of 3.3%.
Analysts rate Rigel Pharmaceuticals Inc a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $63.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.38% |
| Soleus Capital Management, L.P. | 9.87% |
| Armistice Capital, LLC | 8.95% |
| State Street Corp | 5.57% |
| Vanguard Capital Management, LLC | 4.20% |
| American Century Companies Inc | 3.97% |
| LSV Asset Management | 3.86% |
| Acadian Asset Management LLC | 3.17% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 RIGEL PHARMACEUTICALS, INC. - FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total revenues (6 months): $137.5 million vs. $1 | 2026-08-04 |
| Results announced · Q3 2026 RIGEL PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenues: $78.7 million (net product sales $67.0 million + collabor | 2026-08-04 |
| Board / officer change · Q2 2026 RIGEL PHARMACEUTICALS, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Alison L. Hannah, M.D. appointed as Executive Vice President and Chie | 2026-07-01 |
| Acquisition completed · Q2 2026 RIGEL PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Upfront payment to licensors: $70.0 million (one-time, paid upon closing) • Effect | 2026-06-17 |
| Board / officer change · Q2 2026 RIGEL PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 14, 2026 • 500,000 additional shares authorized under amen | 2026-05-20 |
| Quarterly report · Q1 2026 RIGEL PHARMACEUTICALS, INC. — Q1 2026 (10-Q) SUMMARY --- HEADLINE NUMBERS • Total revenues: $58.8 million (Q1 2026) vs. $53.3 million (Q1 2025) — u | 2026-05-05 |
| Proxy statement · Q2 2026 RIGEL PHARMACEUTICALS, INC. — 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three director nominees—Alison Hannah M.D., Wal | 2026-04-03 |
| Annual report FY2025 RIGEL PHARMACEUTICALS, INC. - FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Total Product Revenue (2025): $231.9 mil | 2026-03-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rigel Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.